$7.71
6.61% today
Nasdaq, Apr 01, 07:19 pm CET
ISIN
US01626L1052
Symbol
ALGS
Sector
Industry

Aligos Therapeutics Inc Stock price

$8.25
-8.62 51.10% 1M
-0.41 4.73% 6M
-31.59 79.29% YTD
-15.54 65.31% 1Y
-45.50 84.65% 3Y
-366.75 97.80% 5Y
-366.75 97.80% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.87 9.54%
ISIN
US01626L1052
Symbol
ALGS
Sector
Industry

Key metrics

Market capitalization $50.44m
Enterprise Value $1.77m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.45
P/S ratio (TTM) P/S ratio 12.77
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -74.60%
Revenue (TTM) Revenue $3.95m
EBIT (operating result TTM) EBIT $-89.15m
Free Cash Flow (TTM) Free Cash Flow $-80.87m
Cash position $57.05m
EPS (TTM) EPS $-20.92
P/E forward negative
P/S forward 1.92
EV/Sales forward 0.07
Short interest 19.41%
Show more

Is Aligos Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Aligos Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Aligos Therapeutics Inc forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Aligos Therapeutics Inc forecast:

Buy
100%

Financial data from Aligos Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
3.95 3.95
75% 75%
100%
- Direct Costs 2.62 2.62
15% 15%
66%
1.32 1.32
89% 89%
33%
- Selling and Administrative Expenses 18 18
28% 28%
445%
- Research and Development Expense 70 70
4% 4%
1,779%
-87 -87
2% 2%
-2,191%
- Depreciation and Amortization 2.62 2.62
15% 15%
66%
EBIT (Operating Income) EBIT -89 -89
1% 1%
-2,257%
Net Profit -131 -131
50% 50%
-3,322%

In millions USD.

Don't miss a Thing! We will send you all news about Aligos Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aligos Therapeutics Inc Stock News

Neutral
GlobeNewsWire
6 days ago
SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from three oral presentations at the 34th Annual Meeting of the Asian Pacific Association for the Study of ...
Neutral
GlobeNewsWire
18 days ago
SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to pur...
Neutral
GlobeNewsWire
22 days ago
SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2024.
More Aligos Therapeutics Inc News

Company Profile

Aligos Therapeutics, Inc. develops targeted, curative therapies for hepatologic diseases and viral infections. It engages in building a pipeline of drug candidates which targets multiple clinically validated mechanisms of action and are designed to achieve functional cure for CHB and become transformative treatment options for COVID-19 and NASH. The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.

Head office United States
CEO Lawrence Blatt
Employees 70
Founded 2018
Website www.aligos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today